Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Wave Life Sciences, Inc.

WVENASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Oct 7, 2026Accepted Oct 7, 2026, 9:06 PM EDTFiling CIK 1631574Accession 0001231919-26-001433
Share

Structured filing — 4

form4-10082026_011038.xml

Open full document ↗

Filing details

Report period
2026-10-05
Issuer
Wave Life Sciences, Inc.
Issuer CIK
0001631574
Trading symbol
WVE

Reporting owner 1

Name
RA CAPITAL MANAGEMENT, L.P.
Reporting owner CIK
0001346824
Relationship
Director · 10% owner
Address
200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116

Reporting owner 2

Name
RA Capital Healthcare Fund LP
Reporting owner CIK
0001315082
Relationship
Director · 10% owner
Address
200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116

Reporting owner 3

Name
Kolchinsky Peter
Reporting owner CIK
0001384859
Relationship
Director · 10% owner
Address
C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116

Reporting owner 4

Name
Shah Rajeev M.
Reporting owner CIK
0001619841
Relationship
Director · 10% owner
Address
C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnershipNature of ownership
Common Stock2026-10-05A · Form 410,700[F1]A039,515ISee footnotes[F2][F3]
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
I
Indirect

Non-derivative holdings

Non-derivative holdings · 1 reported row
SecurityAmount ownedOwnershipNature of ownership
Common Stock26,975,505ISee footnotes[F3][F4]
Table key
I
Indirect

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnershipNature of ownership
Stock Option (Right to Buy)3.752026-10-05A · Form 464,000A0[F5]2036-10-05Ordinary Shares64,00064,000ISee Footnotes[F2][F3]
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
I
Indirect

Footnotes

F1
Dr. Kolchinsky was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Issuer's 2027 annual meeting of stockholders or October 5, 2027.↩ 1
F2
Dr. Kolchinsky is a Managing Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Kolchinsky's arrangement with the Adviser, Dr. Kolchinsky holds the RSUs and options for the benefit of the Fund. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or shares received upon settlement of the RSUs, or exercise of the options, as applicable, which will offset advisory fees owed by the Fund to the Adviser.↩ 1↩ 2
F3
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.↩ 1↩ 2↩ 3
F4
Held directly by the Fund.↩ 1
F5
Dr. Kolchinsky was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Issuer's 2027 annual meeting of stockholders or October 5, 2027.↩ 1

Remarks

Dr. Peter Kolchinsky, a Managing Partner of the Adviser, serves on the Issuer's board of directors.

Signature 1

Signed
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Date
2026-10-07

Signature 2

Signed
/s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.
Date
2026-10-07

Signature 3

Signed
/s/ Peter Kolchinsky, individually
Date
2026-10-07

Signature 4

Signed
/s/ Rajeev Shah, individually
Date
2026-10-07

Company context

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s lead pipeline programs include obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008), as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Current securities

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersNov 18, 2026
  2. 10-Q filingOct 27, 2026
  3. Results of Operations and Financial ConditionOct 27, 2026
  4. ARS filingOct 14, 2026
  5. DEF 14A filingOct 14, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.